Alector(ALEC) - 2025 Q4 - Annual Results

Exhibit 99.1 Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysi ...